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ABSTRACT: Background: The Movement Disorder
Society diagnostic criteria for progressive supranuclear
palsy introduced the diagnostic certainty level “sugges-
tive of progressive supranuclear palsy” for clinical
conditions with subtle signs, suggestive of the disease.
This category aims at the early identification of patients,
in whom the diagnosis may be confirmed as the disease
evolves.
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Objective: To assess the diagnostic performance of the
defined clinical conditions suggestive of progressive
supranuclear palsy in an autopsy-confirmed cohort.
Methods: Diagnostic performance of the criteria was ana-
lyzed based on retrospective clinical data of 204 autopsy-
confirmed patients with progressive supranuclear palsy
and 216 patients with other neurological diseases.
Results: The conditions suggestive of progressive supra-
nuclear palsy strongly increased the sensitivity compared
to the National Institute of Neurological Disorders and
Stroke and Society for Progressive Supranuclear Palsy
criteria. Within the first year after symptom onset, 40% of
patients with definite progressive supranuclear palsy ful-
filled criteria for suggestive of progressive supranuclear
palsy. Two-thirds of patients suggestive of progressive
supranuclear palsy evolved into probable progressive
supranuclear palsy after an average of 3.6 years. Appli-
cation of the criteria for suggestive of progressive
supranuclear palsy reduced the average time to diagno-
sis from 3.8 to 2.2 years.
Conclusions: Clinical conditions suggestive of progres-
sive supranuclear palsy allow earlier identification of
patients likely to evolve into clinically possible or proba-
ble progressive supranuclear and to have underlying pro-
gressive supranuclear palsy pathology. Further work
needs to establish the specificity and positive predictive
value of this category in real-life clinical settings, and to
develop specific biomarkers that enhance their diagnos-
tic accuracy in early disease stages. © 2020 The
Authors. Movement Disorders published by Wiley Period-
icals LLC. on behalf of International Parkinson and Move-
ment Disorder Society.
Key Words: progressive supranuclear palsy; clinical
diagnostic criteria; autopsy; suggestive; early diagnosis;
neuropathology
Progressive supranuclear palsy (PSP) is a sporadic,
adult-onset neurodegenerative disease with average dis-
ease duration of approximately 6–8 years. Characteristic
neuropathological findings are intracellular aggregation
of hyperphosphorylated tau protein with four microtu-
bule binding repeat domains (4-repeat tau) in oligoden-
drocytes (coiled bodies), astrocytes (tufted astrocytes),
and neurons (neurofibrillary tangles).1–3 A definite diag-
nosis of PSP can only be established currently by post-
mortem neuropathological brain examination.1,4
In 2017, the Movement Disorder Society-endorsed
PSP study group provided new clinical diagnostic criteria
(MDS-PSP criteria)5 on the basis of an extensive evalua-
tion of the published literature and a large clinico-
pathological cohort.5,6 The diagnostic certainty level
“suggestive of PSP” (s.o. PSP) was introduced with the
intention of allowing an earlier and more sensitive identi-
fication of patients presenting with subtle signs sugges-
tive of PSP that may evolve into clinically possible,
probable PSP later in disease course, and ultimately have
definite PSP on postmortem examination.5
Moreover, PSP predominance types were introduced
by the MDS-PSP criteria as part of the clinical diagno-
sis. Not every predominance type is represented in
every certainty level. There are seven predominance
types for s.o. PSP, five for possible PSP and four for
probable PSP:
• s.o. PSP: PSP-CBS (PSP with predominant cor-
ticobasal syndrome), PSP-F (PSP with predominant
frontal presentation), PSP-OM (PSP with predomi-
nant ocular motor dysfunction), PSP-P (PSP with pre-
dominant parkinsonism), PSP-PI (PSP with
predominant postural instability), PSP-RS (PSP with
Richardson’s syndrome), PSP-SL (PSP with predomi-
nant speech/language disorder);
• possible PSP: PSP-CBS, PSP-OM, PSP-PGF (PSP with
progressive gait freezing), PSP-RS, PSP-SL; and
• probable PSP: PSP-F, PSP-P, PSP-PGF, PSP-RS.
Thus, many patients will change their predominance
type as diagnostic certainty increases.
Three retrospective studies validating the MDS-PSP
criteria have been published to date and compared
them with previous criteria (NINDS-SPSP).7–9 Ali
et al.7 analyzed the overall MDS-PSP criteria in an
autopsy-confirmed cohort with 66 PSP patients and
63 other neurodegenerative diseases (corticobasal
degeneration [CBD], N = 35; frontotemporal lobar
degeneration with TDP pathology [FTLD-TDP], N = 1;
glial globular tauopathy [GGT], N = 3; multiple system
atrophy [MSA], N = 4; Lewy body disease [LBD],
N = 20) and suggested significantly increased sensitivity
(87.9% vs 45.5%) and slightly reduced specificity
(85.7% vs 90.5%) of the MDS-PSP criteria, as com-
pared to the NINDS-SPSP criteria. In this study, the
PSP cohort was divided into an early-stage group with
neurological evaluation within 3 years after symptom
onset and a late-stage group with neurological evalua-
tion after 3 years of symptom onset. In the early-stage
group, the sensitivity for s.o. PSP was 84.4% (N = 45),
while in the late-stage group it reached 100% (N = 37).
The sensitivity for s.o. PSP of the entire cohort was
87.9% (N = 66).7
Another study published by the study group of this
paper analyzed the diagnostic performance of the
MDS-PSP criteria in an independent cohort of
108 autopsy-confirmed PSP cases and 81 cases with
other FTLD pathologies, including syndromes of behav-
ioral variant frontotemporal dementia (bvFTD), non-
fluent/agrammatic variant primary progressive aphasia
(nfvPPA), and corticobasal syndrome (CBS) confirmed
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improved sensitivity for the MDS-PSP criteria com-
pared to the NINDS-SPSP criteria (72.2%–100% vs
48.1%–61.1%, depending on the certainty level) with
reduced specificity (53.1%–95.1% vs 97.5%–100%,
depending on the certainty level).8
We previously analyzed sensitivity and specificity of
the diagnostic category “probable 4-repeat tauopathies”
as part of the MDS-PSP criteria in 195 PSP, 55 CBD,
and 161 non-4-repeat tauopathies.9 These cases were
part of the same cohort analyzed in the current study.
High specificity for PSP and CBD pathology suggested
that MDS-PSP criteria for “probable 4-repeat
tauopathies” are suitable for the recruitment of patients
into therapeutic trials targeting 4R-tau.9
However, the diagnostic performance of the s.o. PSP
category needs further verification. Thus, we aimed to
determine the reliability of the s.o. PSP diagnostic cate-
gory in early identification of patients at risk of pro-
gressing into possible or probable PSP during the
clinical course, and in prediction of underlying PSP
pathology.
Therefore, we analyzed a large, clinically well-
described cohort of autopsy-confirmed PSP patients and
disease controls for (1) the sensitivity, specificity and
positive predictive value (PPV) of s.o. PSP to predict
underlying PSP pathology as a function of disease dura-
tion, (2) the effect of the exclusion criteria thereon,
(3) evolution of patients with s.o. PSP into possible and
probable PSP, (4) the impact of s.o. PSP on the overall
diagnostic performance of the MDS-PSP criteria as
compared to the NINDS-SPSP criteria, and (5) the dis-
tribution of PSP-predominance types among s.o. PSP
with and without PSP pathology.
Methods
Protocol Approvals and Patient Consents
Approval for this work was obtained from the local
IRBs and the Ethics committee of the Technical Univer-
sity of Munich, Germany. Prior to death, all donors
gave written informed consent for the use of their brain
tissue and medical records for research purposes.
Identification of Cases
Patients with autopsy-confirmed diagnoses of
PSP,10–12 corticobasal degeneration (CBD),13 multiple
system atrophy (MSA) with a clinical diagnosis of MSA
with predominant parkinsonism (MSA-P),14 Lewy body
disease (LBD)15 with clinical history of Parkinson’s dis-
ease (PD), and 4R-tau negative frontotemporal lobar
degeneration (non-4RT FTLD)16 were identified in the
registries of nine collaborating brain banks with exper-
tise in neurodegenerative disorders:
1. Neurobiobank Munich, Center for Neuropathology
and Prion Research, Ludwig-Maximilians-Univer-
sity, Munich, Germany.
2. MRC London Neurodegenerative Diseases Brain
Bank, King’s College, London, UK.
3. Netherlands Brain Bank, Amsterdam in collabora-
tion with the Department of Neurology, Erasmus
Medical Center, Rotterdam, The Netherlands.
4. Neurological Tissue Bank of the Biobanc-Hospital
Clinic-IDIBAPS, Barcelona, Spain in collaboration
with the Neurology Department of the Hospital
Clinic.
5. Centre de Ressources Biologiques-Bordeaux Bio-
thèque Santé, Bordeaux, France.
6. Brain Bank of Region Skane, Department of Pathol-
ogy, Lund University, Lund, Sweden.
7. Johns Hopkins Medical Institutions (JHMI) Brain
Resource Center, Baltimore, USA.
8. Penn Center for Neurodegenerative Disease
Research (CNDR) brain bank, University of Penn-
sylvania, Philadelphia, USA.
9. Brain Bank of the Royal University Hospital, Uni-
versity of Saskatchewan, Canada.
The majority of cases that entered these brain banks
originated from tertiary neurological hospitals. The
participating brain banks searched their inventories for
all cases with an autopsy-confirmed diagnosis of PSP,
CBD, LBD, MSA, and non-4RT FTLD. All cases with
LBD pathology had received a clinical diagnosis of PD
or PD with dementia (PDD) prior to death. All cases
with MSA pathology had received a clinical diagnosis
of MSA-P prior to death. All other cases were selected
by pathology, regardless of their clinical diagnosis.
Cases with insufficient clinical data were excluded from
analysis. Cases from the same cohort had been included
in previous studies.6,9
Data Collection
Detailed clinical information was generated for each
patient by retrospective chart review. The following fea-
tures were systematically abstracted: age of onset
(defined as onset of first disease-specific clinical signs),
age of death, gender, and presence/absence and year of
onset of: abnormal saccades, alien limb phenomenon,
Alzheimer’s disease-like deficits, apraxia of limb(s),
apraxia of speech, asymmetry at onset, asymmetry
(persisting), autonomic dysfunction, bradykinesia, cere-
bellar signs, cognitive dysfunction, cortical sensory loss,
dysarthria, dysphagia, dystonia (axial), dystonia of
limb(s), falls, freezing of gait, freezing of speech, frontal
dysfunction, hallucinations (spontaneous), hallucina-
tions (L-dopa-induced), levodopa-responsiveness, myoc-
lonus, non-specific visual symptoms, postural
instability, non-fluent/agrammatic primary progressive
aphasia, pyramidal tract signs, rapid hypophonia, rapid
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micrographia, rest tremor, rigidity (axial predominant),
rigidity (limb predominant), semantic dementia, start
hesitation, supranuclear gaze palsy, and tremor. Defini-
tions for these clinical features are given in Table 1. In
some cases, the year of onset for a respective feature
could not be determined and was therefore recorded as
present at final record. The term “end of record” refers
to a feature being present after the 9th year or at some
point in the disease history without indicated time. Fea-
tures that were not stated as present in the patients´
medical records were considered to be absent.
Validation of the MDS-PSP and the NINDS-
SPSP Criteria
Inclusion and exclusion criteria of the MDS-PSP
criteria and the NINDS-SPSP criteria were applied retro-
spectively to our cohort for each patient and each year
after onset of the first disease-associated symptom. For
our analysis, we interpreted the term “predominant”
used in the context of “impairment of episodic
memory,” “autonomic failure,” “visual hallucinations or
fluctuations in alertness,” and “multisegmental upper
and lower motor neuron signs” in the MDS-PSP exclu-
sion criteria5 as present in the first 2 years of disease.
The presence or absence of core clinical features allowed
the allocation of each patient to a diagnostic certainty
level, which comprised probable, possible, or s.o. PSP
for the MDS-PSP criteria, and probable or possible PSP
for the NINDS-SPSP criteria. The specific predominance
type according to the MDS-PSP criteria was identified
for each patient for each year after symptom onset.
Diagnostic allocations to multiple levels of certainty and
predominance type according to the MDS-PSP criteria
were reduced by applying the Multiple Allocation
eXtinction (MAX) rules.17 Patients with persisting multi-
ple allocations after application of the MAX rules were
handled as separate entities (eg, PSP-P + PSP-F). Sensitiv-
ity, specificity, and PPV for both the MDS-PSP and the
NINDS-SPSP criteria were determined and compared for
the years 1, 3, 6, and 9 and at final antemortem record.
Evolution rates into higher diagnostic certainty levels
were assessed for s.o., possible and probable PSP
according to the MDS-PSP criteria for each year of dis-
ease. Distribution of predominance types among each
diagnostic certainty level and among each pathological
diagnosis were assessed according to the MDS-PSP
criteria.
Results
Patient Demographics
A total of 204 patients with autopsy confirmed PSP,
and 216 cases with other neurological disease (compris-
ing 55 CBD, 50 MSA-P, 51 PD, and 60 non-4RT FTLD
patients) with detailed clinical records were included in
our analysis. Non-4RT FTLD comprised 46 patients
with TAR DNA-binding protein 43 (TDP-43) pathol-
ogy, 10 patients with three-repeat (3R)-tau pathology
(Pick’s disease), and four patients with fused in sarcoma
(FUS) protein pathology. The age of onset of first symp-
toms in the PSP cohort ranged from 41–91 years with a
mean age of 66 years and in the non-4RT cohort from
42–80 years with a mean age of 58 years. Detailed
demographic data of all patients is given in Table 1.
Sensitivity of s.o. PSP
Sensitivity (ie, percentage of correct positive diagno-
ses from all definite PSP patients) of the retrospectively
established diagnosis of s.o. PSP using the MDS-PSP
criteria during the course of the disease (1st, 3rd, 6th, 9th
year after symptom onset and at final antemortem
record) in cases with autopsy-confirmed, definite PSP,
after application of the MDS-PSP exclusion criteria, is
shown in Figure 1A.
In the 1st year, sensitivity of s.o. PSP was 39.7%, con-
tributing the largest proportion of patients to yield an
overall sensitivity of the MDS-PSP criteria of 53.5%.
TABLE 1. Demographic data
Cases Controls
PSP All CBD MSA PD FTLD
N 204 216 55 50 51 60
♂:♀ (N;[%]) 107:97
[52.5:47.5]
112:104
[51.9:48.1]
107:97
[52.5:47.5]
16:34 [32.0:68,0] 25:26 [49.0:51.0] 41:19 [68.3:31.7]
Age at onset (yr, mean  SEM [range]) 66.3  0.6
[41–91]
59.6  0.6
[42–81]
63.8  1.2
[42–81]
59.7  1.3
[45–80]
58.7  1.5
[42–76]
56.8  1.0
[42–74]
Age at death (yr, mean  SEM
[range])
74.1  0.6
[54–94]
68.4  0.6
[47–92]
70.4  1.1
[51–85]
67.1  1.2
[51–90]
73.4  1.2
[59–92]
63.5  1.2
[47–84]
Disease duration (yr, mean  SEM
[range])
7.7  0.3 [0–27] 8.6  0.4 [1–35] 6.8  0.4 [1–12] 7.0  0.3 [2–15] 14.7  1.0
[3–35]
6.9  0.6 [1–20]
Demographic data of autopsy-confirmed PSP patients and disease controls.
Abbreviations: CBD, corticobasal degeneration; non-4RT FTLD, non-4R-tauopathy frontotemporal lobar degeneration; MSA, multiple system atrophy; PD,
Parkinson’s disease; PSP, progressive supranuclear palsy; SEM, standard error of the mean.
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With increasing disease duration, the sensitivity of
s.o. PSP declined (3rd year, 34.3%; 6th year, 25.5%; 9th
year, 24.5%; end of record, 17.6%), whereas the
overall sensitivity of the MDS-PSP criteria increased
(3rd year, 64.2%; 6th year, 71.5%; 9th year, 74.5%;
and end of record, 85.8%).
FIG. 1. Sensitivity, specificity, and positive predictive value with application of the exclusion criteria. (A) Rate of correct positive PSP diagnoses in defi-
nite PSP (ie sensitivity) and (B) false–positive PSP diagnoses in non-4R-tauopathies (ie, 100%-specificity) with the MDS-PSP criteria (probable, possible
or suggestive of PSP) and NINDS-SPSP criteria (probable or possible PSP) as a function of disease duration (1st–9th year) since onset of first symp-
toms. (C) Positive predictive value (PPV) for s.o. PSP (first row), possible or probable PSP combined (second row), and PSP of all certainty levels com-
bined (third row) according to the MDS-PSP criteria; and of all certainty levels combined according to the NINDS-SPSP criteria (possible and probable
PSP; forth row). Abbreviations: EOR, end of record; Prob., probable PSP; poss., possible PSP; s.o., suggestive of PSP. Not identified = patients not ful-
filling the respective clinical diagnostic criteria; excluded = patients meeting the exclusion criteria of the respective clinical diagnostic criteria. [Color fig-
ure can be viewed at wileyonlinelibrary.com]
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Contribution of s.o. PSP to the Overall
Sensitivity of the MDS-PSP Criteria
The sensitivity of the retrospectively established diag-
nosis of possible or probable PSP using the MDS-PSP
or the NINDS-SPSP criteria during the course of the
disease in cases with autopsy-confirmed, definite PSP,
after application of the respective exclusion criteria, is
also shown in Figure 1A.
Considering only the diagnostic certainty levels of
possible and probable PSP, the MDS-PSP criteria
yielded slightly higher sensitivity than the NINDS-SPSP
criteria throughout the entire disease course (1st year,
13.8% vs 8.8%; 3rd year, 29.9% vs 25.0%; 6th year,
46.0% vs 37.2%; 9th year, 50.0% vs 40.7%; and end
of record, 68.2% vs 50.0%).
When the diagnostic certainty level of s.o. PSP was
included in the analysis, the MDS-PSP criteria yielded
much higher sensitivity than the NINDS-SPSP criteria
throughout the entire disease course (1st year 53.5% vs
8.8%, 3rd year 64.2% vs 25.0%, 6th year 71.5% vs
37.2%, 9th year 74.5% vs 40.7%, end of record 85.8%
vs 50.0%).
Effect of the Exclusion Criteria on Sensitivity
We analyzed the effect of correct application versus
omission of the exclusion criteria on the sensitivity of
the MDS-PSP and NINDS-SPSP criteria (Fig. 1A vs
Supplementary Fig. S1A).
The percentage of definite PSP patients fulfilling the
exclusion criteria increased with time (MDS-PSP: 1st year
4.4% to 9th year 7.4%; NINDS-SPSP: 1st year 13.7% to
9th year 18.1%; Fig. 1A), indicating that some patients
with definite PSP develop clinical features that are not
considered as typical for PSP. The fact that this rate was
significantly lower in the MDS-PSP than in the NINDS-
SPSP criteria reflects the inclusion of a broader pheno-
typic spectrum in the former, features that were consid-
ered as exclusion criteria in the latter criteria.
A total of 7% (N = 15) of definite PSP patients met
exclusion criteria of the MDS-PSP criteria within the first
3 years (ie, false–negative cases). The most frequent rea-
son for their exclusion was predominant unexplained
autonomic dysfunction in 10 out of 15 cases (67%),
followed by impairment of episodic memory suggestive
of Alzheimer’s disease in three cases and visual halluci-
nations in one case. There were two cases with dual
pathology, one of them with PSP and LBD and the other
one with PSP and AD pathology. Both of them were
excluded because of autonomic failure within the first
2 years.
Sensitivity of the s.o. PSP category in the MDS-PSP
criteria increased only marginally when the exclusion
criteria were omitted (1st year, 39.7% vs 41.7%; 9th
year, 24.5% vs 27.0%; Fig. 1A vs Supplementary
Fig. S1A).
Overall sensitivity of the MDS-PSP criteria (s.o., pos-
sible, and probable) also increased only marginally,
when the exclusion criteria were omitted (1st year,
53.5% vs 57.4%; 9th year, 74.5% vs 81.9%; and end
of record, 85.8% vs 93.1%; Fig. 1A vs Supplementary
Fig. S1A).
The overall sensitivity of the NINDS-SPSP criteria
(possible and probable) increased only slightly when
the exclusion criteria were omitted (1st year, 8.8% vs
13.8% and 9th year, 40.7% vs 54.0%; Fig. 1A vs Sup-
plementary Fig. S1A). The largest difference in sensi-
tivity when omitting the exclusion criteria could be
seen at the end of record (50.0% vs 75.0%; Fig. 1A vs
Supplementary Fig. S1A). This was the case because a
large number of patients were excluded after the 9th
year, or at final record, because symptoms without
time specification were assumed to be present at the
end of record.
False–Positive s.o. PSP Diagnoses
False–positive diagnoses of s.o. PSP using the MDS-
PSP criteria, after application of the exclusion criteria,
in definite non-PSP cases are shown in Figure 1B. As
expected, s.o. PSP yielded higher rates of false–positive
diagnoses than probable PSP (1st year, 13.9% vs 1.9%;
3rd year, 18.5% vs 5.6%; 6th year, 21.3% vs 11.6%;
9th year, 24.5% vs 13.9%, and end of record, 34.3%
vs 17.6%). Surprisingly, possible PSP yielded only one
false–positive diagnosis at the end of record in this
series.
To identify which patient group would be most prone to
misclassification as s.o. PSP (ie, false–positive cases), we
analyzed false–positive diagnoses in CBD, MSA, PD, and
non-4RT FTLD patients separately (Supplementary Fig. S2,
applying exclusion criteria; Supplementary Fig. S3, without
applying exclusion criteria).
With the application of the exclusion criteria, most
false–positive s.o. PSP diagnoses in the 1st year
occurred in the CBD group with 21.8%
(Supplementary Fig. S2D), followed by the MSA
group with 20% (Supplementary Fig. S2A), and the
PD group with 9.8% (Supplementary Fig. S2A). From
the 3rd until the 9th year, most false–positive s.o. PSP
diagnoses were observed in the MSA group (3rd year
and 9th year 30%, Supplementary Fig. S2A). Most of
these MSA cases received a diagnosis of s.o. PSP-PI
(not shown), which reflects the high prevalence of
early postural instability observed in both MSA and
PSP. When omitting the exclusion criteria, the MSA
group showed the highest prevalence of false–positive
s.o. PSP diagnoses from the 1st year (30%) until the
9th year (48%) (Supplementary Fig. S3A), followed by
the CBD group from the 1st year (27.3%) until the 9th
year (38.2%) (Supplementary Fig. S3D).
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At final record, most false–positive s.o. PSP diagnoses
were observed in PD cases (58.8% with and 62.7%
without applying exclusion criteria), mostly due to pres-
ence of the features A3 (“parkinsonism, with tremor
and/or asymmetric and/or levodopa responsive”) and C2
(“frontal cognitive/behavioral presentation”) qualifying
for s.o. PSP-P.5 Second and third most common false–
positive s.o. PSP diagnoses occurred in the MSA group
(38% with, 56% without exclusion criteria) and in the
CBD group (27.3% with, 36.4% without exclusion
criteria). The difference between the 9th disease year and
final record is based on the fact that the time of onset of
some features was not recorded, thus being only consid-
ered for the final record analysis.
The rate of false–positive s.o. PSP diagnoses in non-
4RT FTLD was 5.0% in the 1st year and continuously
increased to 16.7% until the end of record.
In the first 3 years, 13.9% (30/216) non-PSP patients
presented with postural instability and therefore quali-
fied for s.o. PSP-PI (not shown). This number was sta-
ble until the end of record, because postural instability
must occur within the first 3 years to qualify for a diag-
nosis according to the MDS-PSP criteria. Importantly,
however, 7.9% (17/216) were eliminated by the MDS-
PSP exclusion criteria. At the end of record, the most
frequent s.o. PSP predominance type in non-PSP
patients was s.o. PSP-P with 22.7% (49/216), respec-
tively, 19.9% (43/216) after application of exclusion
criteria.
Overall Specificity of the MDS-PSP and the
NINDS-SPSP Criteria
Specificity is the percentage to which non-PSP
patients were correctly classified as non-PSP (ie, sum of
“not identified” and “excluded”). Specificity of the
overall MDS-PSP criteria (s.o., possible and probable)
was high in the 1st and 3rd year (84.2% and 75.9%)
and declined to 61.5% at year 9 (Fig. 1B). Specificity of
possible and probable MDS-PSP criteria only (consider-
ing s.o. PSP as no diagnosis) was high throughout the
clinical course (MDS-PSP: 1st year, 98.1%; 3rd year,
94.4%; and 9th year, 86.1%). NINDS-SPSP criteria
maintained a higher specificity throughout the course of
disease (1st year, 97.7%; 3rd year, 96.3%;, and 9th year
94.0%; Fig. 1B).
Effect of the Exclusion Criteria on Specificity
We analyzed the effect of application versus omission
of the exclusion criteria on the rate of false–positive
diagnoses of the MDS-PSP and NINDS-SPSP criteria
(Fig. 1B) vs Supplementary Fig. S1B.
Specificity increased when applying the exclusion
criteria, because a number of definite non-PSP patients,
which were falsely classified as PSP, were excluded.
False–positive diagnoses decreased for the MDS-PSP
criteria (1st year s.o. PSP criteria: 19% to 13.9%, over-
all MDS-PSP criteria: 21.3% to 15.8%) and for the
NINDS-SPSP criteria (overall: 4.7% to 2.4%). The
elimination of false–positive PSP diagnoses in non-PSP
patients was more pronounced in later disease stages
(eg, 9th year: s.o. PSP: 33.8% to 24.5%, probable
MDS-PSP: 19.4% to13.9%, overall MDS-PSP: 53.2%
to 38.4%, overall NINDS-SPSP: 13.5% to 6%).
To identify which differential diagnostic group would
benefit most from correct application of the exclusion
criteria, we analyzed false–positive diagnoses in MSA, PD,
and non-4RT FTLD patients separately (Supplementary
Fig. S2, applying exclusion criteria; Supplementary Fig. S3,
without applying exclusion criteria). The elimination of
false–positive diagnoses by the exclusion criteria was by
far strongest for MSA, followed by CBD, then PD, and
finally non-4RT FTLD, both for s.o. MDS-PSP, overall
MDS-PSP, and overall NINDS-SPSP criteria.
Positive Predictive Value of MDS-PSP and
NINDS-SPSP Criteria
PPVs for the MDS-PSP and the NINDS-SPSP criteria
as a function of disease duration are displayed in
Figure 1C. The PPV for s.o. PSP starts off with 73% in
the 1st year and continuously declines to 63.6% in the
3rd year, 48.5% in the 9th year, and 32.7% at the end
of record. Possible and probable PSP combined
according to the MDS-PSP criteria had a PPV of 87.5%
in the 1st year, increasing to 91% in the 3rd year, before
decreasing again to 81% in the 9th year and ending at
81.8% at the end of record. NINDS-SPSP criteria,
which are defined by a possible and probable PSP cate-
gory rise in PPV from 78.3% in the 1st year to 86.4%
in the 3rd year and then fluctuate from 85.4% in the 6th
year to 86.5% in the 9th year back to 86.4% at the end
of record. The overall PPV of the MDS-PSP criteria was
76.2% in the 1st year, 71.6% in the 3rd, 64.7% in the
9th year, and 60.8% at the end of record.
Effect of the Exclusion Criteria on the Positive
Predictive Value
We also analyzed the effect of the exclusion criteria
on the PPV (Fig. 1C vs Supplementary Fig. S1C). With
the omission of the exclusion criteria, PPV was
reduced for all patient groups of our cohort in every
year and for both the MDS-PSP and the NINDS-SPSP
criteria.
Evolution of s.o. PSP into Higher Clinical
Diagnostic Certainty Levels
Figure 2A shows the initial allocation of the
204 autopsy confirmed PSP patients into their MDS-
PSP diagnostic certainty category (downward arrows)
and the evolution into higher levels of certainty (col-
ored arrows). Only few definite PSP patients (7%,
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N = 14) were not identified at all by the MDS-PSP
criteria before death. Few definite PSP patients (7%,
N = 15) met an exclusion criterion, of which two
patients were first recognized as s.o. PSP and two as
probable PSP. The vast majority of cases received an
initial diagnosis of s.o. PSP (57%, N = 116), followed
by probable PSP (27%, N = 55), and possible PSP
(4%, N = 8).
FIG. 2. Allocation of definite PSP patients into the MDS-PSP diagnostic certainty levels. (A) Initial allocation and categorical evolution of diagnostic cer-
tainty levels of the MDS-PSP criteria showing the quantitative relevance of the s.o. PSP category as most frequent first clinical diagnosis in N = 204
definite PSP cases. Percentages in the arrows refer to the amount of patients in the circle at the beginning of the arrow. Definite PSP is a neuropatho-
logical diagnosis and therefore can only be stated post mortem. (B) Time-dependent evolution rates of diagnostic certainty levels per year of the MDS-
PSP criteria showing that MDS s.o. PSP category is a highly frequent transition stage. Last a.m., last ante mortem diagnosis; last p.m., last post mor-
tem diagnosis; Prob., probable PSP; Poss., possible PSP; S.o., suggestive of PSP; Def., definite PSP. Not identified = patients not fulfilling the diagnos-
tic criteria; excluded = patients meeting the exclusion criteria of the clinical diagnostic criteria. [Color figure can be viewed at wileyonlinelibrary.com]
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During their clinical evolution, s.o. PSP patients later
met the MDS-PSP exclusion criterion of autonomic fail-
ure within the first 2 years of disease (2%, N = 2),
remained s.o. PSP until final antemortem record (31%,
N = 36), or evolved to possible PSP (1%, N = 1) or
probable PSP (66%, N = 77).
Time-dependent evolution rates of diagnostic cer-
tainty levels per year after symptom onset in the
204 definite PSP patients are visualized in a Sankey dia-
gram (Fig. 2B). A diagnosis of s.o. PSP was present in
40% of patients (N = 81) in the first year.
With time, the number of s.o. PSP patients continu-
ously declined to 2% (N = 4) at the last antemortem
record, mainly due to transition into definite PSP
(i.e. death) or probable PSP.
The majority of s.o. PSP patients (66%, N = 77)
evolved into probable PSP, on average after 3.6 years.
Consistently, the number of patients with probable PSP
steadily increased from the first year (12%, N = 24) to
a maximum in the 4th year (27%, N = 55), before con-
tinuously declining again, due to the increasing number
of deceased patients qualifying for definite PSP.
Frequencies of PSP Predominance Types
Figure 3 shows the relative frequencies and temporal
evolution of clinical predominance types in definite PSP
patients for the entire cohort (top row), for the subgroups
fulfilling the clinical criteria for s.o. PSP (second row), and
for possible or probable PSP patients (lower row).
In the total cohort, PSP-PI was prevailing initially (1st
year, 33.3%), PSP-RS becoming predominant only after
year 3 (3rd year, 27.0%). In the s.o. PSP group, PSP-PI
was the most common predominance type throughout
the clinical course (1st year, 80.0%; 3rd year, 70.7%,
and 9th year, 56.4%). In possible or probable PSP
patients, PSP-RS was the most frequent predominance
FIG. 3. Predominance types of definite PSP patients by the MDS-criteria for the diagnosis of PSP. Data are shown as a function of disease duration
(1st–9th year) since onset of first symptoms. The top row shows all patients, the middle row patients fulfilling clinical suggestive of (s.o.) PSP criteria,
the lower row patients fulfilling possible or probable PSP criteria. EOR, end of record; Prob., probable PSP; poss., possible PSP; s.o., suggestive of
PSP; PSP-RS, PSP with Richardson’s syndrome; PSP-PI, PSP with predominant postural instability; PSP-OM, PSP with predominant ocular motor
dysfunction; PSP-PGF, PSP with progressive gait freezing; PSP-P, PSP with predominant Parkinsonism; PSP-F, PSP with predominant frontal presen-
tation; PSP-SL, PSP with predominant speech/language disorder; PSP-CBS, PSP with predominant corticobasal syndrome. Not identified = patients
not fulfilling the diagnostic criteria. [Color figure can be viewed at wileyonlinelibrary.com]
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type throughout (1st year, 68.8%; 3rd year, 77.5%; 9th
year, 70.5%).
Transition of PSP Predominance Types
A detailed analysis of how patients transition between
the different MDS-PSP predominance types during the
disease course is shown in Figure 4. Certainty levels are
disregarded in this figure.
N = 77 (38%) of all patients changed their predomi-
nance type during their clinical course, as demonstrated in
detail in Supplementary Table S4. More than half (41/77;
53%) of the transitions occurred within the first 4 years.
The transition from PSP-PI to PSP-RS was by far the most
common (65/77; 84%). The transition from any predomi-
nance type to PSP-RS took 2.9 years on average.
Time to Diagnosis
For the MDS-PSP criteria, the average time to first
PSP diagnosis after onset of first symptoms was
2.2  0.23 (range = 1–26) years using the criteria in
FIG. 4. Transition of MDS predominance types between 1st and 10th year and at the end of record in N = 204 definite PSP patients. Each column repre-
sents 1 year, the size of the colored columns and the size of the connection strings is representative to the amount of patients. EOR, end of record;
PSP-RS, PSP with Richardson’s syndrome; PSP-PI, PSP with predominant postural instability; PSP-OM, PSP with predominant ocular motor dysfunc-
tion; PSP-PGF, PSP with progressive gait freezing; PSP-P, PSP with predominant Parkinsonism; PSP-F, PSP with predominant frontal presentation;
PSP-SL, PSP with predominant speech/language disorder; PSP-CBS, PSP with predominant corticobasal syndrome. Not identified = patients not ful-
filling the diagnostic criteria; excluded = patients meeting the exclusion criteria of the clinical diagnostic criteria. [Color figure can be viewed at
wileyonlinelibrary.com]
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general, 2.1  0.31 (range = 1–26) years for s.o. PSP,
2.0  0.44 (range = 1–4) years for possible PSP, and
3.9  0.28 (range = 1–19) years for probable PSP. The
combined time to diagnosis of possible and probable
PSP was 3.8  0.27 (range = 1–19).
For the NINDS-SPSP criteria, the average time to
diagnosis was 4.0  0.3 (range = 1–18) years in gen-
eral, 4.7  0.5 (range = 1–18) years for possible PSP,
and 3.4  0.4 (range = 1–15) years for probable PSP.
Discussion
Our study shows that the novel concept of s.o. PSP
contributes to the increased sensitivity of the MDS-PSP
criteria for antemortem PSP diagnosis, compared to the
NINDS-SPSP criteria in our cohort. The majority of
PSP patients in our cohort passed through the state of
s.o. PSP diagnosis (57%) and evolved to a higher level
of diagnostic certainty antemortem (66%). Among
those that evolved to probable or possible PSP in our
cohort, the average time PSP patients spent with a diag-
nosis of s.o. PSP before evolving was 3.6 years. How-
ever, as the prevalence of PSP in our cohort is a lot
higher than in the average neurological clinic popula-
tion, further investigation with a more representative
population should be assessed in future projects.
S.o. PSP showed high specificity in the first 3 years of
disease, declining with increasing disease duration.
Application of the MDS-PSP criteria for s.o. PSP
reduced the time to diagnosis by 1.6 years from 3.8 to
2.2 years on average. When compared to the NINDS-
SPSP criteria, the overall time to diagnosis was reduced
from 4.0 years (NINDS-SPSP) to 2.2 years (MDS-PSP).
In total, 57% (N = 116) of all PSP patients in our
cohort received a diagnosis of s.o. PSP at any time until
the end of record, 69.8% (N = 81) of these cases within
the 1st year after symptom onset and 86.2% (N = 100)
within the first 3 years after symptom onset. Hence,
s.o. PSP is essential to identify prospect PSP patients at
an early disease stage and should play an important role
for future research projects, such as clinical trials with
disease modifying therapies to stop disease progression
at an early stage. Considering that patients who were
identified as possible or probable PSP also fulfilled
s.o. PSP criteria, only 12% (N = 25) of the patients did
not meet MDS-PSP criteria for s.o. PSP, either because
they met exclusion criteria (5%) or they lacked necessary
features (7%). These numbers need to be validated with
a prospective study to see if further adjustments are pos-
sible to raise the sensitivity even more.
Sensitivity of s.o. PSP and the overall MDS-PSP
criteria was lower in our study than in a previous study
by Ali et al.7 For s.o. PSP, Ali et al.7 found a sensitivity
of 46.7% within the first 3 years of disease, compared
to 34.3% in our cohort, and a sensitivity of 100% for
the late stage group of >3 years disease duration, com-
pared to 85.7% in our cohort. Sensitivity of the overall
MDS-PSP criteria within the first 3 years was also lower
in our cohort, with 84.4% in Ali et al.,7 compared to
64.2% in our cohort. The fraction of patients with
s.o. PSP at the end of record was very similar with
17.8% in the study by Ali et al.7 and 17.6% in our
cohort. Specificity of the overall MDS-PSP criteria was
higher in our study. Within the first 3 years, specificity
was 75.9%, compared to 34.2% in Ali et al.7 One rea-
son for the discrepancy in specificity could be the com-
position of the disease control group. In the cohort of
Ali et al.,7 the control group also consisted of patients
with CBD pathology, which made up 55.6% of the
control group (88.9% met MDS-PSP criteria), whereas
our control group consisted only 55 patients with CBD,
which made up 25.5% of the entire control cohort.
Moreover, most cases of the autopsy cohort presented
in our study were used to develop the MDS-PSP
criteria.6 This circularity in the analysis may have led to
a general overestimation of the performance of the
MDS-PSP criteria in our cohort.
The most frequent predominance type in s.o. PSP in
our cohort was PSP-PI. At the same time, s.o. PSP-PI
was the most frequent false–positive diagnosis in early
stages in disease controls, especially in MSA-P cases.
S.o. PSP-PI is defined as (1) repeated unprovoked falls
within 3 years (P1), or (2) tendency to fall on the pull-
test within 3 years (P2) according to the MDS-PSP
criteria.5 In our retrospective data, details on the pull-test
were not documented. Any documentation of repeated
unprovoked falls within 3 years was considered as P1
and any documented postural instability within 3 years
without documented falls was considered as P2. Thus, it
is possible that details on performance in the pull-test
would increase the number of cases diagnosed as
s.o. PSP-PI. The presence of two or more steps backward
on the pull test (P3) could not be assessed with our data,
which is a limitation of the study. For a diagnosis of
s.o. PSP-RS and s.o. PSP-F, an abnormal pull test can be
decisive. Therefore, these predominance types are likely
to be underrepresented in our cohort. Moreover, fre-
quent macro square wave jerks, one of the features that
characterize O3 were not documented. For meeting O3,
an eyelid opening apraxia can be sufficient, however, its
presence or absence was only reported in 19% of our
cases and present in 9% of our cases. These likely imple-
ments an observation and recruitment bias into the dis-
tribution of the predominance types in our cohort.
Adequate consideration of these features might increase
sensitivity of s.o. PSP in a prospective setting, which
highlights the importance of the pull-test and oculomotor
evaluation in the early clinical diagnosis of PSP. Further,
the high relative frequency of PSP-SL in patients with
s.o. PSP underlines the importance of considering speech
and language symptoms as initial presentation of PSP.
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In our cohort of definite PSP patients, a majority
(66%) of PSP patients diagnosed as s.o. PSP evolved
into probable PSP, within an average time of 3.6 years.
The evolution was mostly due to the development of
abnormal saccades or supranuclear gaze palsy in
patients with a diagnosis of s.o. PSP-PI, which subse-
quently qualified for probable PSP-RS. For interpreting
the transition between different predominance types, it
is crucial to keep in mind that not every predominance
type is represented in every certainty level. PSP-PI is
only represented in the s.o. PSP category, and therefore,
disease progression makes a transition of PSP-PI to
another predominance type very likely. Patients with
PSP-F and PSP-P can be allocated to s.o. PSP and prob-
able PSP. Hence, a progress in the same predominance
type is possible. The high number of evolving patients
emphasizes the relevance of s.o. PSP as a transition
stage into higher levels of diagnostic certainty.
The number of PSP patients diagnosed as possible
PSP according to the MDS-PSP criteria was very low
(5%). This may be due to clinical data that could not
be determined in our cohort and is one of the limita-
tions of this study. Indeed, a diagnosis of possible PSP
with PSP-RS requires the presence of P3,5 and thus,
was not documented in our cohort. Moreover, possible
PSP with predominant ocular motor dysfunction (PSP-
OM) and possible PSP with progressive gait freezing
(PSP-PGF) are each defined by one clinical feature only:
vertical supranuclear gaze palsy (O1) and progressive
gait freezing within 3 years (A1), respectively. When
they are combined with other diagnostic clinical fea-
tures, a diagnosis of probable PSP applies, as was the
case for most of our analyzed patients. When regarding
the results of our study, the design of the possible PSP
category can be questioned. Further investigation in
form of prospective studies will show whether the lim-
ited value of the category possible PSP is caused by the
retrospective design of our study.
Specificity of the overall MDS-PSP criteria depended
on the diagnostic certainty and the year after disease
onset. In our cohort, s.o. PSP showed high levels of
specificity within the first 3 years of disease, which
declined with longer disease duration.
The PPV for possible and probable PSP according to
the MDS-PSP criteria was high and superior to the PPV
of the NINDS-SPSP criteria until the 3rd year and
remained above 80% until the end of record. The PPV
for s.o. PSP decreased with increasing disease duration
to 67% at end of record. This is mainly due to the
increasing numbers of non-PSP cases being diagnosed
with PSP-PI and PSP-SL in the early years and PSP-P in
later years of the disease.
Because specificity and PPV depend on the number of
cases per disease group included into the analysis, our
results on specificity and PPV should be interpreted
with caution. Increasing the numbers of CBD, MSA-P,
or PD patients or including patients with other 4R-
tauopathies, like globular glial tauopathy (GGT) or
argyrophilic grain disease (AGD), would likely result in
lower specificity and lower PPV. However, for thera-
peutic strategies that focus on tau or 4R-tau, dis-
tinguishing PSP from other 4R-tauopathies probably
will not be decisive.
If the intention was to recognize any 4R-tauopathy,
the specificity and PPV for both diagnostic criteria are
underestimated, because the CBD patients included in
our cohort significantly reduced the PPVs.
The MDS-PSP exclusion criteria excluded fewer PSP
patients, but also fewer non-PSP patients, as compared
to the NINDS-SPSP criteria. There are at least two rea-
sons for this: on the one hand, “severe, asymmetric par-
kinsonian signs,” which are part of the NINDS-SPSP
exclusion criteria, does not apply for the MDS-PSP
criteria; on the other hand, our retrospective setting did
not allow us to judge the severity of a symptom. Thus,
we interpreted “predominant” as “present within the
first 2 years of disease” for all respective MDS-PSP
exclusion criteria that include this term. These are
(1) “predominant, otherwise unexplained impairment of
episodic memory, suggestive of Alzheimer dementia”;
(2) “predominant, otherwise unexplained autonomic
failure, eg, orthostatic hypotension, suggestive of multi-
ple system atrophy, or Lewy body disease”; and (3) “pre-
dominant, otherwise unexplained visual hallucinations
or fluctuations in alertness, suggestive of dementia with
Lewy bodies.” Thus, in a prospective setting, “predomi-
nant” could also apply for features with later onset and
lead to the exclusion of further patients. A large number
of the excluded PSP patients (33.8%) developed
amnestic symptoms suggestive of Alzheimer’s disease in
the late disease course in our cohort. These cases met the
NINDS-SPSP exclusion criteria (“cortical dementia of
Alzheimer type”), but not the MDS-PSP exclusion
criteria, (“predominant, otherwise unexplained impair-
ment of episodic memory, suggestive of Alzheimer
dementia”). Another 36.7% of the patients excluded by
the NINDS-SPSP criteria had “severe asymmetric parkin-
sonian signs,” which is not an exclusion criterion of the
MDS-PSP criteria. Thus, the MDS-PSP exclusion criteria
do exclude less true PSP patients from a clinical diagno-
sis compared to the NINDS-SPSP criteria, while still
maintaining an acceptable specificity. Omission of the
MDS-PSP exclusion criteria would not yield a meaning-
ful increase in sensitivity, but reduce specificity, and is
therefore not recommended.
In summary, this study describes the characteristics
and clinical evolution of patients diagnosed with
s.o. PSP. It highlights the considerable value of s.o. PSP
in identifying patients in their early clinical course, who
evolve to develop possible or probable PSP and are
likely to have underlying PSP pathology. Recognition of
clinical conditions s.o. PSP reduce the time to first PSP
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diagnosis by 1.6 years on average. PSP patients remained
with a diagnosis of s.o. PSP for 3.6 years on average
before evolving to a higher level of diagnostic certainty.
With the ultimate goal to deliver disease-modifying ther-
apies within the earliest clinical course, it will be of high
importance to further characterize patients with s.o. PSP
in a prospective, real-life clinical setting and to identify
biomarkers to increase the specificity of PSP or 4R-
tauopathy diagnosis early on. The limitations of this
study arise mainly through its retrospective nature, use
of the development cohort for validation, and focus on
those with known neuropathology, rather than prospec-
tive cases in community or healthcare settings. Thus,
prospective validation of the diagnosis of s.o. PSP will be
mandatory to verify our results.
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